LLY

754.62

+0.26%↑

JNJ

176.82

-0.47%↓

ABBV

216.68

+0.24%↑

UNH

341.39

-2.01%↓

AZN

77.65

-0.21%↓

LLY

754.62

+0.26%↑

JNJ

176.82

-0.47%↓

ABBV

216.68

+0.24%↑

UNH

341.39

-2.01%↓

AZN

77.65

-0.21%↓

LLY

754.62

+0.26%↑

JNJ

176.82

-0.47%↓

ABBV

216.68

+0.24%↑

UNH

341.39

-2.01%↓

AZN

77.65

-0.21%↓

LLY

754.62

+0.26%↑

JNJ

176.82

-0.47%↓

ABBV

216.68

+0.24%↑

UNH

341.39

-2.01%↓

AZN

77.65

-0.21%↓

LLY

754.62

+0.26%↑

JNJ

176.82

-0.47%↓

ABBV

216.68

+0.24%↑

UNH

341.39

-2.01%↓

AZN

77.65

-0.21%↓

Home・Aandelen Lijst・uniQure NV

uniQure NV

Open

14.9 -2.17

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.7

Max

15.33

Belangrijke statistieken
By Trading Economics
Inkomsten	5.9M -38M
Verkoop	3.7M 5.3M
Winstmarge	-716.819
Werknemers	209
EBITDA	-4.5M -44M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+138.65% upside

Dividenden
By Dow Jones
Volgende Winsten	4 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	136M 956M
Vorige openingsprijs	17.07
Vorige sluitingsprijs	14.9

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

10.05 / 14.75 Steun & Weerstand

uniQure NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2024, 15:18 UTC

Belangrijke Marktbewegers

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Peer Vergelijking

Prijswijziging

uniQure NV Prognose

Koersdoel

By TipRanks

138.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 39.33 USD 138.65%

Hoogste 70 USD

Laagste 24 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor uniQure NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan uniQure NV - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

10.05 / 14.75Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.